DIVISLAB Divi's Laboratories Q1 FY26 results (Apr–Jun 2025) and concall
Divi's Laboratories delivered strong Q1 FY26 results with consolidated total income growing 15.11% and PAT up 26.74% YoY, driven by robust performance in the nutraceutical business and a forex gain. The company is strategically advancing its custom synthesis and peptide synthesis capabilities, supported by the new Kakinada Unit 3. However, persistent generic pricing pressures, geopolitical uncertainties, and extended timelines for regulatory approvals for new products remain key areas of focus and potential concern.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,302 | 2,297 | 2,536 | 2,357 |
| EBITDA | 729 | 747 | 881 | 743 |
| Net profit | 518 | 594 | 667 | 557 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
